SAN FRANCISCO & MELBOURNE, Australia--(BUSINESS WIRE)--Immuron Ltd. (ASX: IMC), a biopharmaceutical company specializing in oral immunotherapy development and antibody manufacturing, announced today approval for a Phase II human clinical study in HIV/AIDS patients at a prestigious U.S. AIDS research center, and the award of a prestigious research grant for an HIV antibody. The announcement was made during the 27th Annual J.P. Morgan Healthcare Conference in San Francisco.
